Study to assess immunogenicity, reactogenicity and safety of primary vaccination with GSK Biologicals' MenACWY vaccine (GSK134612) given as 1 or 2 doses to healthy toddlers 9-12 months of age.

Trial Profile

Study to assess immunogenicity, reactogenicity and safety of primary vaccination with GSK Biologicals' MenACWY vaccine (GSK134612) given as 1 or 2 doses to healthy toddlers 9-12 months of age.

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Oct 2016

At a glance

  • Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
  • Indications Meningococcal infections
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 26 Feb 2016 Pooled 5 years antibody persistence and booster response analysis of 2 studies including this and the follow-up trial (see CTP 700229951) were published in the Pediatric Infectious Disease Journal.
    • 29 Jul 2008 Actual completion date added (Jul 2008) as reported by ClinicalTrials.gov.
    • 29 Jul 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top